Clinical and Experimental Medicine

, Volume 14, Issue 4, pp 355–360

Tocilizumab: a new therapy for large vessel vasculitis

Review Article

DOI: 10.1007/s10238-013-0254-5

Cite this article as:
Al-Homood, I.A. Clin Exp Med (2014) 14: 355. doi:10.1007/s10238-013-0254-5


Large vessel vasculitis represents mainly two main diseases: giant cell arteritis and Takayasu arteritis. Recent advancements in the treatment for different rheumatic diseases refractory to disease-modifying antirheumatic agents with biologic agents have resulted in remarkable efficacy and tolerability. However, treatments for large vessel vasculitis (LVV) with tumor necrosis factor-α inhibitors have yielded conflicting results. Recently, very promising results have been reported in patients treated with tocilizumab. The purpose of this review is to summarize the current treatment strategies of LVV and the recent evidence on the use of tocilizumab in LVV.


Giant cell arteritis Large vessel vasculitis Takayasu arteritis Tocilizumab 

Copyright information

© Springer-Verlag Italia 2013

Authors and Affiliations

  1. 1.College of MedicineAl Imam Mohammad Ibn Saud Islamic UniversityRiyadhSaudi Arabia

Personalised recommendations